Table 4.
Multivariate analysis of factors associated with outcomes of patients with pre-transplantation MRD who underwent allo-SCT both in the retrospective study and the prospective study (n = 141)
| Covariate | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P value | |
| Relapse | ||||||
| Disease status (CR1 vs. CR > 1) | 4.736 | 2.113–10.617 | <0.001 | 5.852 | 2.569–13.652 | <0.001 |
| Transplant modality | 0.318 | 0.142–0.712 | 0.005 | 0.360 | 0.159–0.813 | 0.014 |
| Chronic GVHD (yes vs. no) | 0.834 | 0.712–0.977 | 0.024 | 0.793 | 0.669–0.939 | 0.007 |
| FLT3-ITD (yes vs. no) | 2.710 | 0.914–8.041 | 0.072 | |||
| Transplant-related mortality | ||||||
| Recipient age | 1.051 | 0.998–1.108 | 0.061 | |||
| Neutrophil engraftment | 1.213 | 1.019–1.445 | 0.030 | 1.213 | 1.019–1.445 | 0.030 |
| Leukemia-free survival | ||||||
| Disease status (CR1 vs. CR > 1) | 3.542 | 1.715–7.318 | 0.001 | 4.554 | 2.127–9.752 | <0.001 |
| Transplant modality | 0.300 | 0.149–0.602 | 0.001 | 0.334 | 0.165–0.677 | 0.001 |
| Chronic GVHD (yes vs. no) | 0.812 | 0.705–0.934 | 0.004 | 0.783 | 0.675–0.909 | 0.001 |
| FLT3-ITD (yes vs. no) | 2.501 | 0.951–6.575 | 0.063 | |||
| Overall survival | ||||||
| Disease status (CR1 vs. CR > 1) | 2.634 | 1.171–5.923 | 0.019 | 2.269 | 1.002–5.137 | 0.049 |
| Transplant modality | 0.309 | 0.143–0.670 | 0.003 | 0.340 | 0.155–0.743 | 0.007 |
All variables were first included in the univariate analysis; only variables with P < 0.1 were included in the Cox proportional hazards model with time-dependent variables
Abbreviations: MSDT human leukocyte antigen-matched sibling donor transplantation, HR hazard ratio, CI confidence interval, EBMT European Group for Blood and Marrow Transplantation